Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors

Journal of Clinical Outcomes Management

Volumn 16, Issue 5, 2009, Pages 215-223

  Halpern, Rachel ^a   Barghout, Victoria ^b,c   Zarotsky, Victoria ^a   Williams, Denise E ^b  

^a Health Economics and Outcomes Research   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ARTICLE; BILLING AND CLAIMS; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; COMPARATIVE STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; UNITED STATES;

EID: 67650485799     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Chronic myelogenous leukemia. Available at www.nccn.org/ professionals/physician- gls/PDF/cml.pdf. Accessed 27 Mar 2009.
2. Simonsson B; IRIS (International Randomized IFN vs STI571) Study Group. Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS study [abstract]. Blood 2005;106:166.
3. Guilhot F, Roy L, Guilhot J, et al. Retrospective comparison of imatinib versus interferon plus cytarabine (IFN/Ara-c) for chronic myelogenous leukemia (CML) patients in chronic phase (CP) [abstract]. Blood 2005;106:165.
4. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:7583-93.
5. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
6. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
7. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101:97-100.
8. Cervantes F; IRIS (International Randomized IFN vs. STI571) Study Group. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (CML): 24-month update from the IRIS Study [abstract]. Blood 2003; 102:633.
9. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003;102:83-6.
10. Hughes T, Branford S, Matthews J, et al. Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase [abstract]. Blood 2003;102:31a.
11. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomepositive chronic phase chronic myeloid leukemia. Blood 2004; 103:2873-8.
12. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623-9.
13. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
14. Demetri GD, Benjamin RS, Blanke CD, et al; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines [published erratum appears in J Natl Compr Canc Netw 2007;5:xxx]. J Natl Compr Canc Netw 2007;5 Suppl 2:S1-29.
15. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
16. Blanke CD, Joensuu H, Demetri GD, et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four-year follow-up of a phase II randomized trial [abstract]. Presented at the ASCO 2006 Gastrointestinal Cancers Symposium; 2006 Jan 26-28; San Francisco, CA.
17. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96.
18. Lin EH, Von Korff M, Ludman EJ, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry 2003;25:303-10.
19. Lahdenperä TS, Kyngäs HA. Compliance and its evaluation in patients with hypertension. J Clin Nurs 2000;9:826-33.
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
21. Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000;1:35-47.
22. Russell CJ, Dean MA. To log or not to log: bootstrap as an alternative to the parametric estimation of moderation effects in the presence of skewed dependent variables. Organ Res Methods 2000;3:166-85.
23. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
24. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) [abstract]. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(Suppl):6119.
25. Wu EQ, Feng W, Johnson S, et al. Medical costs associated with imatinib (IM) non-compliance in chronic myeloid leukemia (CML) patients (pts) [abstract]. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl):17514.
26. Pindolia VK, Zarowitz BJ. Imatinib mesylate the first molecularly targeted gene suppressor. Pharmacotherapy 2002;22: 1249-65.
27. Goldman J. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients? Nat Clin Pract Oncol 2005;2:126-7.
28. Peggs K. Imatinib mesylate - gold standards and silver linings. Clin Exp Med 2004;4:1-9.
29. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 2005;9:1-142.
30. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515-26.
31. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005;25: 325-34.
32. Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004;26:1924-33.
33. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574-83.